Literature DB >> 2985750

Benzodiazepine receptor and thyroid hormones: in vivo and in vitro modulation.

J H Medina, E De Robertis.   

Abstract

In rats rendered hyperthyroid by chronic treatment with L-triiodothyronine (T3) hormone there was a 21 and 27% decrease, respectively, in the number of binding sites for [3H]flunitrazepam ([3H]FNZ) and [3H]ethyl-beta-carboline-3-carboxylate ([3H]beta-CCE) without changes in affinity for the two ligands. Two weeks after thyroidectomy there was a 44% increase in [3H]FNZ sites and a 17% increase in [3H]beta-CCE binding sites. In vitro we found that T3 produces a decrease in Bmax and an increase in KD, both changes being characteristic of a mixed type of inhibition. Thyroid status dramatically affected the Ki of T3 in displacing [3H]FNZ from sites on isolated membranes of the cerebral cortex: in hypothyroid rats the Ki value was 0.9 microM, whereas in hyperthyroid rats, it was 83 microM, a 92-fold difference. In control rats, the Ki was 11 microM. These findings are discussed in relation to a possible modulation of benzodiazepine receptors by thyroid hormones.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985750     DOI: 10.1111/j.1471-4159.1985.tb08767.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  Nuclear benzodiazepine binding: possible interaction with thyroid hormone receptors.

Authors:  Y Dalezios; N Matsokis
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

2.  Effect of thyroid status on beta-adrenoceptors and calcium channels in rat cardiac and vascular tissue.

Authors:  M H Hawthorn; P Gengo; X Y Wei; A Rutledge; J F Moran; S Gallant; D J Triggle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

3.  Kinetics of drug action in disease states. XXXI. Effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine (oxazepam) in rats.

Authors:  J S Walker; P M Klockowski; G Levy
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.